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Background: Progressive familial intrahepatic cholestasis type 1 (PFIC1), an inherited liver disease caused by mutations
in ATP8B1, progresses to severe cholestasis with a sustained intractable itch. Currently, no effective therapy has been
established for PFIC1. Decreased function of the bile salt export pump (BSEP) in hepatocytes is suggested to be
responsible for the severe cholestasis observed in PFIC1. We found a previously unidentified pharmacological
effect of 4-phenylbutyrate (4PB) that increases the expression and function of BSEP. Here, we tested 4PB therapy
in three patients with PFIC1.
Methods: The therapeutic potency of 4PB in these patients was tested by oral administration of this drug with
gradually increasing dosage (200, 350, and 500 mg/kg/day) for 6 months. Biochemical, histological, and clinical
data were collected.
Results: 4PB therapy had no beneficial effect on the patients’ liver functions, as assessed by biochemical and histological
analyses, despite an increase in hepatic BSEP expression. However, therapy with 4PB at a dosage of 350 or
500 mg/kg/day significantly relieved the intractable itch. Serum levels of potential pruritogens in cholestasis were
much higher than the reference ranges during the 4PB therapy.
Conclusions: 4PB therapy may be a new medication for patients with intractable cholestatic pruritus and may
improve quality of life for patients and their families.
Keywords: Pediatric liver disease, Cholestasis, PFIC1, Pruritus, 4PBBackground
Progressive familial intrahepatic cholestasis type 1 (PFIC1),
a rare inherited autosomal recessive liver disease caused by
mutations in ATP8B1, is characterized primarily by normal
serum gamma-glutamyl transferase (GGT), intrahepatic
cholestasis and jaundice in the first year of life [1]. This dis-
ease progresses to severe cholestasis with sustained intract-
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article, unless otherwise stated.pancreatitis, and deafness, resulting in liver failure and
death before adulthood [2]. The main complaint in the
clinical course of patients with PFIC1 is often intract-
able itching, which significantly disrupts the patients’
ability to sleep and thus decreases the quality of life of
patients and their families [3]. No effective medical
therapy for this disease is currently available [3]. Even
liver transplantation is insufficient to improve the clin-
ical course and outcomes of patients with PFIC1 be-
cause of steatosis and fibrosis [4].
ATP8B1 is a member of the P4 subfamily of P-type ad-
enosine triphosphatases and is expressed on the apical
membrane of many epithelial cells including hepatocytes.
ATP8B1 translocates phosphatidylserine (PS) from the
outer leaflet to the inner leaflet and thereby contributes totral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
Hasegawa et al. Orphanet Journal of Rare Diseases 2014, 9:89 Page 2 of 9
http://www.ojrd.com/content/9/1/89making the hepatocanalicular membrane (CM) a rigid,
liquid-ordered membrane [5,6]. In patients with PFIC1,
the well-organized aminophospholipid asymmetry of the
CM is disrupted by the impaired function of ATP8B1,
leading to a decrease in the transport activity of the bile
salt export pump (BSEP), an ABC transporter that is local-
ized on the CM and that predominantly mediates biliary
excretion of bile salts [7-10], and subsequently to the on-
set of severe intrahepatic cholestasis [11]. Alternatively, in
patients with PFIC1, nuclear translocation of the farnesoid
X receptor (FXR), a transcription factor that controls bile
acid homeostasis, is disrupted and causes a decrease in
BSEP expression at the CM because of mass action related
to the decreased expression of BSEP mRNA [12]. There-
fore, in either cause of PFIC1, an increase in BSEP func-
tion is expected to compensate for the reduced capacity
for bile salt excretion into bile in patients with PFIC1, and
may improve their liver function.
We have published experimental evidence that 4-
phenylbutyrate (4PB), a drug used to treat ornithine
transcarbamylase deficiency (OTCD), has another newly
identified pharmacological effect that increases the hepa-
tocanalicular expression of BSEP and the hepatocyte
capacity for biliary excretion of bile salts when given at a
clinically relevant concentration in OTCD patients [13].
The higher BSEP expression level in liver specimens
from patients with OTCD after 4PB therapy compared
with that before 4PB therapy suggests that 4PB treat-
ment increases BSEP expression in humans [14]. Further-
more, our group and Gonzales et al. reported recently
that 4PB therapy restored decreased BSEP expression, im-
proved liver functions in histological and biochemical ana-
lysis, and relieved intractable pruritus in patients with
PFIC type 2 (PFIC2), an inherited autosomal recessive
liver disease caused by mutations in BSEP [15,16]. PFIC2
patients present with similar clinical symptoms and bio-
logical parameters as PFIC1 patients [17,18]. Together,
these results suggest the possibility that 4PB may be a po-
tential therapeutic compound for PFIC1 patients that
could act to restore the reduced capacity of biliary excre-
tion of bile salt through increasing BSEP expression on
the CM.
To test this hypothesis, our current study investigated
the effects of 4PB therapy in three PFIC1 patients. 4PB
was administered orally with gradually increasing dosage
(200, 350, and 500 mg/kg/day) for 6 months. We col-
lected data on serum liver tests, histological analyses,
pruritus score, and the clinical course for these patients.
Methods
We obtained approval for the study from the institu-
tional ethics review boards. Informed consent was ob-
tained from the patients’ parents before assessment
because the patients were younger than 18 years of age.A detailed description of the materials and methods is
presented in the Additional file 1. All materials and
methods used standard techniques and commercially
available reagents.
Patients
The patients enrolled in our study were three Japanese boys
(Patient 1, 2, and 3) who were seen at Osaka University
Hospital in 2012 and aged 2-, 6-, and 16-years old, re-
spectively. All three patients developed hepatocellular
cholestasis with mild elevation of serum aspartate ami-
notransaminase (AST) and alanine amino transaminase
(ALT) levels and normal GGT levels as infants and ex-
perienced sleep disturbance because of intractable itch
at around 4, 6, and 4 months of age, respectively. Pa-
tient 3 had difficulty in getting to sleep by the end of
elementary school. Despite treatment with drugs in-
cluding ursodeoxycholic acid, topical steroids, and anti-
histamine agents for 1.5, 5, and 15 years in patient 1, 2,
and 3, respectively, these patients continued to experi-
ence severe cholestasis with sustained intractable itch,
jaundice, diarrhea, and failure to thrive, which are typ-
ical clinical symptoms of PFIC1. The patients and/or
their families preferred medical treatment to surgical
procedure like partial external biliary diversion. There-
fore, the patients were enrolled in this clinical study.
The administration of original drugs was maintained
during and after the course of 4PB treatment. The
drugs given to the patients before, during, and after the
course of this study are listed in the Additional file 1:
Table S1.
Sequence analysis of ATP8B1 and ABCB11
Genomic DNA was isolated from peripheral blood leu-
kocytes using a Wizard Genomic DNA Purification Kit
(Promega, Madison, WI), and all exons of ATP8B1 and
ABCB11 and flanking intron–exon boundaries were ana-
lyzed as described previously [16,19,20].
Treatment of PFIC1 patients with 4PB
Oral administration of 4PB (Ammonaps; Swedish Orphan
Inter AB., Stockholm, Sweden) was started at a daily
dosage of 200 mg/kg/day divided into four doses a day.
After 1 month, the dosage was increased to 350 mg/kg/
day and this was maintained for an additional month.
Because neither a therapeutic effect nor any side effects
were observed, the dosage was increased to 500 mg/kg/
day, which is the clinically relevant dosage for OTCD,
and this dosage was maintained for the next 4 months.
A liver biopsy sample was collected 1 day before and
after the course of 4PB treatment. A part of the sample
was preserved in RNAlater (Qiagen, Hilden, Germany) for
RNA preparation and stored at −20°C. Another portion
was fixed in 10% formaldehyde at room temperature for
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frozen in liquid nitrogen for preparation of membrane
fractions and stored at −70°C in a deep freezer. Serum was
collected before, during, and after the course of 4PB treat-
ment. Liver function tests were performed using standard
methods immediately after collection, and the remaining
specimens were preserved at −70°C for further analysis.
Pruritus evaluation
Pruritus severity was scored as reported previously [21]:
0, none; 1, mild scratching when undistracted; 2, active
scratching without abrasion; 3, abrasions; or 4, cutane-
ous mutilation, with bleeding and scarring.
Quantitative determination of pruritogen levels in serum
The concentration and activity of autotaxin (ATX) in
serum were assessed using a specific two-site enzyme
immunoassay and the measurement of choline liberated
from the substrate lysophosphatidylcholine as described
previously [16,22].
Histological analysis of the patients’ liver specimens
Liver biopsy specimens were fixed in 10% formalin and
embedded in paraffin. Four-micrometer-thick sections
were prepared from the liver specimens and subjected to
hematoxylin-eosin (HE) staining and immunohistochem-
istry followed by microscopic analysis with an Olympus
CX41 or Olympus BX40 microscope (Olympus, Tokyo,
Japan) to evaluate the degree of cholestasis, fibrosis, and
inflammation in the liver tissues.
Preparation of crude membrane, nuclear, and cytosolic
fractions from the patients’ liver specimens
Liver specimens from the patients were homogenized in
hypotonic buffer (1 mM EDTA, 5 mM sodium phosphate,
pH 7.0) supplemented with protease inhibitor cocktails
(Sigma-Aldrich, St. Louis, MO) using a QIAshredder
(Qiagen), and then centrifuged at 800 × g for 10 min at
4°C. The supernatant was ultracentrifuged at 100,000 × g
for 1 h at 4°C and the pellet and supernatant were used as
the crude membrane and cytosolic fractions, respectively.
After centrifugation at 800 × g, the pellet was suspended
with high salt buffer (20 mM Tris–HCl pH 7.9, 400 mM
NaCl, 0.1 mM EDTA, 0.1 mM EGTA Na, 0.1% NP-40,
1 mM DTT, 10% glycerol, 0.1% protease inhibitor cock-
tail), incubated on ice for 50 min with vortex mixing every
10 min, and centrifuged at 3000 × g for 10 min at 4°C, and
the supernatant was used as the nuclear extract.
Immunoblotting
Specimens were loaded into each well of a 7% SDS-
PAGE plate with a 3.75% stacking gel, and subjected to
immunoblotting as described previously [13,14,23]. Im-
munoreactivity was detected with an ECL Advance™Western Blotting Detection Kit (Amersham Biosciences,
Piscataway, NJ). The intensity of the band was quantified
by MultiGauge software (version 2.0; Fujifilm, Tokyo,
Japan). Expression levels of ATP8B1, BSEP, and CDC50A
were normalized by the expression of Na+, K+-ATPase
α1 subunit (NaKα1), which was not affected by the treat-
ment with 4PB (data not shown).
Results
Diagnosis of PFIC1 in the patients
Sequencing analysis of all encoding exons and flanking
intron–exon boundaries of ATP8B1 identified a hetero-
zygous mutation c.3033–34del (frame shift or splicing
defect) in patient 1 and a heterozygous mutation c.1587–
89del (p.F529del) in patient 2 (Table 1). The c.1587–89del
(p.F529del) mutation has been reported previously in
European PFIC1 patients of Caucasian descent [19]. Al-
though no other mutations were found in ATP8B1 on the
other allele, as was the case for several PFIC1 patients
reported in a previous study [19], both patients were di-
agnosed with PFIC1 because they exhibited the typical
clinical symptoms of PFIC1 and because of the low
mRNA expression and no detectable protein expression
of ATP8B1 in their liver biopsy specimens (Figure 1A,
B). The near absence and marked decrease of hepatic
ATP8B1 mRNA in patients 1 and 2 may be explained
by other mutations in the promoter region and/or un-
translated region (UTR) of ATP8B1 on the other allele
that affect transcription of ATP8B1 and/or stabilization
of ATP8B1 mRNA. Patient 3 was diagnosed with PFIC1
because of lower mRNA and protein expression of
ATP8B1 in his liver specimen (Figure 1A, B) and be-
cause of his clinical symptoms including intrahepatic
cholestasis with normal GGT, intractable itching, fail-
ure to thrive, and deafness. The sequencing analysis of
ATP8B1 in patient 3 identified c.234C > G (p.H78Q)
(rs3745079) and c.2021 T >C (p.M674T) (rs35470719) mu-
tations on one allele and a mutation c.1729A >G (p.I577V)
(rs3745078) on the other allele. However, given that
these mutations had no significant effect on mRNA and
protein expression, trafficking to the plasma membrane,
and PS flippase activity of ATP8B1 in in vitro studies
(Additional file 2: Figure S1 A–D), it is likely that the
decreased mRNA and protein expression of ATP8B1 in
this patient is caused by mutations in the promoter re-
gion and/or UTR of ATP8B1 that affect transcription of
ATP8B1 and stabilization of ATP8B1 mRNA, but not
by the mutations analyzed in this study.
Therapeutic effect of 4PB in PFIC1 patients
During the period of 4PB treatment, no improvement
was observed in liver function tests for any of the pa-
tients (Figure 2). However, their itching started to at-
tenuate in patient 1 three weeks after the dosage of 4PB
Table 1 ATP8B1 mutation and biochemical parameters in patients enrolled in this study




Patient 1 M 2 c. 3033-3034del (Frame shift) Not found 83/60/36 4.8/4.6/301.3 4
Patient 2 M 6 c.1585-1587TTCdel (p.F529del) Not found 81/15/27 3.4/3.2/214.1 4
Patient 3 M 16 c.234C > G (p.H78Q) c.202IT > C (p.M674T) c.1729A > G (p.I577V) 63/51/19 0.6/0.3/54.6 4
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after the dosage was increased to 500 mg/kg/day, and in
patient 3 four weeks after the dosage of 4PB was in-
creased to 350 mg/kg/day. The itching score declined
from 4 to 2 in all patients (Figure 3A, B). Although there
were multiple dark erosions in the skin of all patients
and elephantiasis in patient 3 due to intense and contin-
ual scratching, after the onset of 4PB treatment at the
dosage of 350 or 500 mg/kg/day, the frequency and in-
tensity of skin scratching was markedly decreased, lead-
ing to diminished skin erosion and hemorrhage and
improved skin appearance (Figure 3C). At the end of theFigure 1 Studies of liver biopsy specimens obtained from the patient
liver sections. Liver sections prepared from the liver biopsy specimens of the p
described in Patients and Methods. A typical image under each condition is sh
expression levels. cDNA (A), crude membrane fractions (B), and nuclear and cy
patients and then analyzed by qPCR (A) and immunoblotting (B and C) as de
triplicate determination. Each bar represents the mean ± SE of individual specim
that of NaKα1, LaminA, and EEA1 is presented below each panel. AU, arb
patient 3; 4PB(−), before 4PB treatment; 4PB(+), after 4PB treatment.therapy, hemorrhage and eschar on the patients’ skin
were diminished and areas of fresh normal skin were
evident. The parents of the patients noted an improve-
ment in sleep disturbance during the night and in their
child’s skin condition. In contrast to the relief of the
itching, the serum levels of bile acids and ATX and of
ATX activity, all of which have been proposed as poten-
tial pruritogens in cholestasis [24], were not decreased
by 4PB therapy in any of the patients (Figures 2B, 3A, B).
The itch remained unchanged for 6, 4, and 6 weeks after
cessation of 4PB therapy in patients 1, 2, and 3, res-
pectively, but then gradually exacerbated, resulting ins before and after 4PB therapy. (D) Histological characteristics of
atients before and after the 4PB therapy were subjected to HE staining as
own. Original magnification; 200×. (A-C) Analysis of mRNA and protein
tosolic fractions (C) were prepared from liver biopsy specimens from the
scribed in Materials and Methods. In (A), the data were obtained from
ens. In (B and C), the signal intensity of ATP8B1, BSEP, and FXR relative to
itrary unit; P-gp, P-glycoprotein; P1, patient 1; P2, patient 2; P3,
Figure 2 Liver function testing before, during and after the course of 4PB therapy in the patients. Serum AST, ALT, GGT (A), total bilirubin, direct
bilirubin, and bile acids (B) levels were monitored before, during and after the 4PB therapy. T-Bil, total bilirubin; D-Bil, direct bilirubin; BA, bile acids.
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of intense scratching. In all the patients, 8 weeks after
the end of 4PB therapy, the itching score returned to
values equal to those before the treatment (Figure 3A, B).
Because of the bad taste of 4PB, all patients had dif-
ficulty taking the doses at the beginning of the therapy.
However, their parents noted the improvement in their
child’s sleep during the night and in the skin condi-
tions, and encouraged their child to continue the ther-
apy. No patients dropped out of this study. No severe
side effects were observed during and after the 4PB
therapy. The temporary elevation of AST and ALT
concentrations after patient 3 began 4PB treatment at
200 mg/kg/day was thought to be caused by adenovirus
infection and not by any adverse effect of the 4PB ther-
apy, because both markers increased promptly after
the adenovirus infection appeared and decreased to the
basal levels concurrently with recovery from the infec-
tion (Figure 2A).
Effect of 4PB therapy on liver histology and BSEP
expression in PFIC1 patients
A liver biopsy was performed 6 months after the initi-
ation of 4PB therapy and compared with the specimens
obtained 1 day before onset of 4PB therapy. The speci-
mens of the age-matched control subjects were obtained
from OTCD patients without administration of 4PBwhen they underwent liver transplantation. qPCR and
immunoblot analysis demonstrated that even in the
specimens taken after the 4PB therapy, the mRNA ex-
pression of ATP8B1 was still much lower in all the pa-
tients than that of age-matched control subjects, and
ATP8B1 protein expression in the membrane fraction
was undetectable in patients 1 and 2. In patient 3,
ATP8B1 expression was increased about 2-fold by 4PB
therapy, but still lower than that in age-matched con-
trol subjects (Figure 1B, C). This result was consistent
with the lack of change in ATP8B1–FLAG F529del and a
2.1- and 1.3-fold increase in ATP8B1H78Q+M674T–FLAG
and ATP8B1I577V–FLAG in UPS-1 cells after treatment
with 4PB at a clinically relevant concentration (1 mM)
(Additional file 3: Figure S2). BSEP protein expression was
increased after 4PB therapy without affecting its mRNA
expression as is the case in patients with PFIC2 and
OTCD (Figure 1A, B) [14,16]. The amount of FXR in the
nuclear fraction of cells from the PFIC1 patients was
nearly equal to or a little higher than that of age-matched
control subjects, and was not significantly affected by 4PB
therapy except for patient 2 (Figure 1C). In this patient,
the amount of FXR was increased 3-fold after 4PB ther-
apy. Histological analysis showed that in the specimens
obtained from the PFIC1 patients before this study, the
portal area was enlarged and had progressed to fibrosis
with mild inflammation and partly bridging fibrosis and
Figure 3 Itching intensity in the patients before, during, and after the course of 4PB therapy. (A, B) Correlation diagram of itching scores
for the PFIC1 patients with serum ATX activity (A) and ATX level (B) in the patients before, during, and after 4PB therapy. Pruritus severity was
scored ranging from 0 (no pruritus) to 4 (cutaneous mutilation, with bleeding and scarring) as described in Patients and Methods. (C) Skin of the
patients before and after the 4PB therapy.
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features (Figure 1D).
Discussion
The main complaint in the clinical course of PFIC1 is
often the intractable itching, which significantly disrupts
the patients’ activities of daily living, work productivity,
and ability to sleep, and thereby decreases the quality of
life for them and their families [2]. Topical steroids, anti-
histamine agents, and rifampicin are the only prescribed
drugs currently available for the cholestatic pruritus in
PFIC1 patients, but these medications are often ineffect-
ive, as was the case for the patients enrolled in this study[3]. The principal finding of our current study is that
4PB therapy at a clinically relevant dosage used in
OTCD patients markedly relieved intractable cholestatic
pruritus in PFIC1 patients. At the end of the therapy,
hemorrhage and eschar on the patients’ skin were dimin-
ished, and areas of fresh normal skin appeared as the
frequency and intensity of skin scratching decreased.
Parents of the patients noted that 4PB therapy made it
easier for their child to get to sleep and markedly re-
duced their child’s sleep disturbance during the night.
Thus, favorable outcomes of 4PB therapy were observed,
and these were dose-dependent, although the patients
and their families in this clinical study were not
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tients and their families were not informed of this aspect
and that the drugs prescribed for 1.5, 5, and 15 years in
patient 1, 2, and 3, respectively, before this study were
ineffective in improving the sustained intractable itch
suggest that the relief of refractory cholestatic itching in
these PFIC1 patients occurred because of the 4PB ther-
apy and not because of a placebo effect or an effect of
other medications.
The visual analog scale (VAS) is the most general
method for assessing pruritus, but is not easily applied
to younger children because VAS is a graphic method
based on the patients’ subjective rating of symptoms
[25]. Therefore, in this study, the patients’ itching was
evaluated on the basis of cutaneous findings and scored
according to the method used in a previous report [21].
A potential concern when using this method is that the
improvement in itch may be underestimated. The sever-
ity of skin erosion, thickness, and cicatrices depends on
the duration of the itch and can vary in the patients
scored as 4. Therefore, there may have been a time lag
in the improvements in skin appearance even if the fre-
quency and intensity of scratching decreased to the same
degree in all patients. In this study, the improvement of
pruritus in patient 3, who experienced intractable prur-
itus for a longer period than patients 1 and 2, might
have been underestimated compared with that in pa-
tients 1 and 2. To overcome this limitation, it might be
better to apply the 5-D itch scale, a recently developed
method that assesses the subjective symptoms of itching
in patients from five dimensions: degree, duration, direc-
tion, disability and distribution [25]. In the 5-D itch
scale, but not in the VAS, the subjective symptoms re-
ported by the patient can be supported by his/her fam-
ily. Therefore, in future clinical studies, the change in
chronic pruritus in younger patients should be explored
using the 5-D itch scale as well as the method used in
this study. This should allow a more accurate determin-
ation of the clinical outcomes and the beneficial effects of
4PB therapy on cholestatic pruritus in PFIC1 patients.
In contrast to the relief of intractable cholestatic itch-
ing, beneficial effects of 4PB therapy were not observed
in liver function tests and liver histology despite an in-
crease in BSEP expression in liver membrane fractions
as reported previously (Figure 1B, D and 2) [14,16]. This
could be because a two- to three-fold increase in BSEP
expression may be insufficient to improve intrahepatic
cholestasis in PFIC1 patients. The other possible reason
is that the transport activity of BSEP is lost completely
in PFIC1 patients because of the disrupted lipid asym-
metry of the CM [6,11] and, consequently, the increase
in BSEP expression by 4PB therapy cannot compensate
for the reduced capacity of bile salt excretion into bile.
Although no remarkable improvement in liver functionwas observed in the patients in our study, 4PB therapy
might have therapeutic potency for specific PFIC1 pa-
tients with mutations in ATP8B1 that attenuate ATP8B1
expression, but do not affect its protein activity. An
in vitro analysis has shown that treatment with 4PB
partially restored the decreased expression of ATP8B1
caused by p.G308V, p.D454G, and p.D544N, all of which
are naturally occurring mutations [26]. Future clinical
studies should validate the therapeutic effect of 4PB and
its safety for use in PFIC1 patients who carry mutations
that attenuate ATP8B1 expression but do not affect its
protein activity.
At present, the mechanism underlying the relief of
cholestatic pruritus by 4PB therapy remains to be eluci-
dated. No decrease in the factors suspected to be caus-
ally associated with cholestatic pruritus (Figures 2, 3A, B)
are consistent with the observation in PFIC2 patient
during 4PB therapy [16]. 4PB and/or its metabolites may
modulate the local concentrations of these pruritogens,
which may not have been detected by systemic measure-
ments. The physiological function of ATX, an enzyme
secreted extracellularly that generates lysophosphatidic
acid, is thought to be mediated predominantly by activa-
tion of G protein-coupled receptors (GPCRs) [27].
TGR5, a GPCR activated by bile salts, in sensory nerves
could contribute to bile salt-induced itching [28]; if so,
4PB and/or its metabolites might antagonize the GPCRs
responsible for itch signaling and therefore attenuate the
activation of sensory neurons. Alternatively, 4PB therapy
may disrupt pruriceptive projections to the brain
through distribution of 4PB and/or its metabolites into
the brain [29] or may affect pruritogens or anti-
pruritogens that have not been identified yet. Further
studies to test these possibilities will provide a better
understanding of the mechanisms responsible for the
effects of 4PB therapy on cholestatic pruritus and thereby
the molecular mechanism of cholestatic pruritus itself.
Information obtained from these studies will contribute
to the development of new molecular target drugs for
cholestatic pruritus, which will hopefully be more effect-
ive than 4PB and consequently, improve the clinical
application of 4PB.
Conclusions
Our study has provided clinical evidence that 4PB ther-
apy can relieve the refractory itching in PFIC1 patients,
and thereby improved the quality of life of the patients
and their families. Future clinical studies with more pa-
tients and longer time periods than were possible in this
study should be undertaken to confirm the favorable ef-
fects of 4PB therapy using the 5-D itch scale and the
other method used in this study. If confirmed, 4PB ther-
apy could become the preferred choice, instead of topical
steroids, antihistamine agents, and surgical procedures,
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and benign intrahepatic cholestasis type 1 (BRIC1), a her-
editary disorder characterized by mutations in ATP8B1
and by recurrent and intermittent episodes of cholestasis
with refractory cholestatic pruritus [30]. 4PB therapy
might also be effective for intractable pruritus caused by
other cholestatic disorders such as Alagille syndrome.
Clinical trials will be required to determine the utility and
safety of 4PB as a therapy for these diseases.
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